Want to see MREO full AI Analyst Report?
Mereo Biopharma Group Plc (MREO) Ratios
Mereo Biopharma Group Plc Ratios
MREO's free cash flow for Q2 2026 was $-6.04M. For the 2026 fiscal year, MREO's free cash flow was increased by $0.00 and operating cash flow was $-6.04M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 10.46 | 5.40 | 6.72 | 3.09 | 7.92 |
| Quick Ratio | 10.46 | 5.40 | 6.72 | 3.09 | 7.92 |
| Cash Ratio | 9.53 | 5.04 | 6.05 | 2.80 | 7.47 |
| Solvency Ratio | -8.14 | -2.73 | -1.78 | -1.58 | 0.35 |
| Operating Cash Flow Ratio | -7.20 | -2.37 | -2.23 | -2.00 | -0.42 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -5.93 | 0.00 | -3.66 | 0.00 |
| Net Current Asset Value | $ 40.02M | $ 59.34M | $ 47.80M | $ 49.19M | $ 82.37M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.08 | 0.09 | 0.20 | 0.13 |
| Debt-to-Equity Ratio | 0.00 | 0.11 | 0.12 | 0.30 | 0.19 |
| Debt-to-Capital Ratio | 0.00 | 0.10 | 0.11 | 0.23 | 0.16 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.08 | 0.00 | 0.14 |
| Financial Leverage Ratio | 1.12 | 1.25 | 1.32 | 1.51 | 1.44 |
| Debt Service Coverage Ratio | -158.72 | -5.91 | -8.86 | -2.26 | 4.49 |
| Interest Coverage Ratio | -150.03 | -34.56 | -9.86 | -15.97 | -5.41 |
| Debt to Market Cap | 0.00 | 0.01 | 0.01 | 0.15 | 0.10 |
| Interest Debt Per Share | 0.00 | 0.05 | 0.07 | 0.16 | 0.24 |
| Net Debt to EBITDA | 1.01 | 1.55 | 1.98 | 1.32 | -4.08 |
| Profitability Margins | |||||
| Gross Profit Margin | 73.40% | 0.00% | 74.26% | 0.00% | 50.89% |
| EBIT Margin | -8324.60% | 0.00% | -271.17% | 0.00% | 50.03% |
| EBITDA Margin | -8094.80% | 0.00% | -260.56% | 0.00% | 51.79% |
| Operating Profit Margin | -7651.40% | 0.00% | -284.16% | 0.00% | -57.42% |
| Pretax Profit Margin | -8375.60% | 0.00% | -299.98% | 0.00% | 39.05% |
| Net Profit Margin | -8375.60% | 0.00% | -294.66% | 0.00% | 34.90% |
| Continuous Operations Profit Margin | -8375.60% | 0.00% | -294.66% | 0.00% | 34.90% |
| Net Income Per EBT | 100.00% | 100.00% | 98.23% | 94.74% | 89.35% |
| EBT Per EBIT | 109.46% | 91.32% | 105.57% | 82.84% | -68.02% |
| Return on Assets (ROA) | -91.20% | -56.62% | -44.31% | -54.41% | 10.05% |
| Return on Equity (ROE) | -102.35% | -70.94% | -58.31% | -81.95% | 14.43% |
| Return on Capital Employed (ROCE) | -91.93% | -75.73% | -49.84% | -101.19% | -18.35% |
| Return on Invested Capital (ROIC) | -91.49% | -68.86% | -48.40% | -75.97% | -16.31% |
| Return on Tangible Assets | -92.24% | -57.10% | -45.05% | -54.41% | 12.47% |
| Earnings Yield | -63.04% | -8.35% | -9.67% | -46.55% | 9.20% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.25 | 0.00 | 2.68 | 0.00 | 0.00 |
| Payables Turnover | 0.10 | 0.45 | 1.10 | -0.07 | 7.82 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 1.31 | 0.00 | 6.06 | 0.00 | 14.38 |
| Asset Turnover | 0.01 | 0.00 | 0.15 | 0.00 | 0.29 |
| Working Capital Turnover Ratio | 0.01 | 0.00 | 0.19 | 0.00 | 0.67 |
| Cash Conversion Cycle | -2210.64 | -818.22 | -196.45 | 4950.94 | -46.67 |
| Days of Sales Outstanding | 1447.59 | 0.00 | 136.22 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 3658.23 | 818.22 | 332.67 | -4950.94 | 46.67 |
| Operating Cycle | 1447.59 | 0.00 | 136.22 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.19 | -0.22 | -0.16 | -0.40 | -0.06 |
| Free Cash Flow Per Share | -0.19 | -0.23 | -0.16 | -0.40 | -0.07 |
| Dividend Paid and CapEx Coverage Ratio | -1548.55 | -46.97 | -50.43 | -3755.46 | -9.79 |
| Capital Expenditure Coverage Ratio | -1548.55 | -46.97 | -50.43 | -3755.46 | -9.79 |
| Operating Cash Flow Coverage Ratio | -153.32 | -5.11 | -3.55 | -3.18 | -0.31 |
| Operating Cash Flow to Sales Ratio | -61.94 | 0.00 | -2.11 | 0.00 | -0.14 |
| Free Cash Flow Yield | -46.65% | -6.48% | -7.07% | -53.97% | -4.17% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -1.60 | -11.97 | -10.34 | -2.15 | 10.88 |
| Price-to-Sales (P/S) Ratio | 132.86 | 0.00 | 30.47 | 0.00 | 3.80 |
| Price-to-Book (P/B) Ratio | 1.62 | 8.49 | 6.03 | 1.76 | 1.57 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -2.14 | -15.44 | -14.14 | -1.85 | -23.97 |
| Price-to-Operating Cash Flow Ratio | -2.14 | -15.77 | -14.42 | -1.85 | -26.42 |
| Price-to-Earnings Growth (PEG) Ratio | 0.00 | 0.12 | 0.28 | 0.01 | -0.10 |
| Enterprise Value Multiple | -0.63 | -11.14 | -9.72 | -0.94 | 3.24 |
| Enterprise Value | 25.64M | 454.36M | 253.20M | 37.67M | 82.69M |
| EV to EBITDA | -0.63 | -11.14 | -9.72 | -0.94 | 3.24 |
| EV to Sales | 51.28 | 0.00 | 25.32 | 0.00 | 1.68 |
| EV to Free Cash Flow | -0.83 | -13.55 | -11.75 | -0.77 | -10.61 |
| EV to Operating Cash Flow | -0.83 | -13.84 | -11.98 | -0.77 | -11.69 |
| Tangible Book Value Per Share | 0.25 | 0.41 | 0.37 | 0.43 | 0.73 |
| Shareholders’ Equity Per Share | 0.26 | 0.41 | 0.38 | 0.43 | 1.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.02 | 0.05 | 0.11 |
| Revenue Per Share | 0.00 | 0.00 | 0.08 | 0.00 | 0.42 |
| Net Income Per Share | -0.26 | -0.29 | -0.22 | -0.35 | 0.15 |
| Tax Burden | 1.00 | 1.00 | 0.98 | 0.95 | 0.89 |
| Interest Burden | 1.01 | 1.03 | 1.11 | 1.09 | 0.78 |
| Research & Development to Revenue | 35.53 | 0.00 | 1.74 | 0.00 | 0.65 |
| SG&A to Revenue | 46.02 | 0.00 | 1.84 | 0.00 | 0.44 |
| Stock-Based Compensation to Revenue | 15.20 | 0.00 | 0.49 | 0.00 | 0.09 |
| Income Quality | 0.74 | 0.76 | 0.72 | 1.16 | -0.37 |
Currency in USD